{
  "docId": "019de070-9f9d-7718-acb6-17a3db6270ac",
  "docSlug": "7a58434f86a94bb0eba92fad9f688c31",
  "documentTitle": "23andMe | SPAC Presentation Deck | 47 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 47,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Uses a comparison frame to highlight competitive advantage in drug development metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-9f9d-7718-acb6-17a3db6270ac/27",
  "deckHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac",
  "deckJsonHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac.json",
  "deckAnchorHref": "/decks/019de070-9f9d-7718-acb6-17a3db6270ac#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Comparison of industry vs 23andMe metrics for time-to-IND and failure rate",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fe27415-29aa-4d46-99d7-460bc2b40043",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "IND = Investigational New Drug Application. Probability of success <12%.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25b89eb1-633f-436d-8512-49bbba1b7c14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "NATURE PUBLICATION: The support of human genetic evidence for approved drug indications, Nelson et. al 2015",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37999674-40e8-4025-8198-73142152d18b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "title",
      "text": "23andMe Can Efficiently Develop Novel Therapeutics by Power, Need and Speed",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09785384-58a1-4057-b17b-ccf23656137e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "edfa5067-1b38-4b15-af43-6af8f7ef0104",
      "evidence": "The slide includes a comparison of industry vs 23andMe metrics for time-to-IND and failure rate in a bar chart, which can be interpreted as a 2x2 matrix.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "15134474-b026-46b3-9770-5b0df969f81c",
      "evidence": "Direct comparison of industry metrics vs company metrics",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "128379fa-90aa-4c0d-b5c6-fef3f5f859b3",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "The Breakthrough",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "The deck presents 23andMe's breakthroughs in therapeutics discovery and development",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 26,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f21fb50b-1139-4a89-a2de-f93a9b6f603d",
      "evidence": "The deck highlights the limitations of current therapeutics development approaches",
      "position": 1,
      "objective": "The cost of inaction in therapeutics development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}